Researchers at University of Utah Health say they have identified a protein that appears to help drive the progression of obesity-related metabolic liver disease from excess fat accumulation into inflammation, scarring and eventual failure. The protein, EFHD1, seems to trigger a misplaced antiviral immune response that damages liver tissue, and blocking it reduced injury in human cells and mouse models.
A protein linked to injury, not just fat buildup
The findings, published in the Journal of Clinical Investigation, come from a team led by David Eberhardt and Dipayan Chaudhuri. According to the researchers, EFHD1 stands out because it is associated with liver injury rather than simply with the presence of excess liver fat. That distinction matters, they said, because many current drug approaches focus on lipid metabolism, while the new work points to a separate pathway that may determine whether a fatty liver becomes damaged.
In the study, excess lipids were shown to increase EFHD1 levels. That rise caused mitochondria to divide too aggressively, leaking material into the cell and activating an antiviral defense pathway. The researchers said the liver cells behaved as if they were under viral attack, even though the stress was being driven by metabolic disease rather than infection.
Blocking EFHD1 lowered inflammation and scarring
When the team reduced or blocked EFHD1, inflammation and liver scarring fell by roughly 30% to 60% in diet-induced and drug-induced mouse models, as well as in human liver organoids. The researchers also reported that mice engineered to lack EFHD1 appeared to maintain normal activity, weight gain and other metabolic measures, suggesting the target could have limited side effects if translated into therapies.
The study authors said they are now working to develop treatments that reduce EFHD1 levels, building on a patent filed by the university. They also plan to examine whether the same pathway contributes to injury in metabolic diseases affecting the heart or to alcohol-related liver damage.
Why the finding matters for patients
Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, but only some patients progress to the more serious stages marked by scarring and liver failure. By identifying a mechanism tied to that transition, the researchers say the work could help shape a complementary treatment strategy alongside existing approaches that focus on fat metabolism.
As Chaudhuri put it in the study, targeting the injury process itself may offer a new opportunity for people whose disease does not fully respond to current therapies. For now, the findings remain preclinical, but they add to growing interest in therapies that intervene earlier in the chain of damage before irreversible liver disease develops.
Source: News-Medical report
Photo source: AI-generated or edited image
